Director/PDMR Shareholding | 20-Nov-2024 | 16:00 | RNS |
Tagrisso recommended for EU approval - LAURA | 18-Nov-2024 | 07:00 | RNS |
Director/PDMR Shareholding | 15-Nov-2024 | 14:00 | RNS |
Director/PDMR Shareholding | 15-Nov-2024 | 10:00 | RNS |
Director/PDMR Shareholding | 13-Nov-2024 | 16:00 | RNS |
AstraZeneca invests $3.5 billion in US | 12-Nov-2024 | 07:10 | RNS |
KOMET Phase III trial met primary endpoint | 12-Nov-2024 | 07:05 | RNS |
9M and Q3 2024 Results | 12-Nov-2024 | 07:00 | RNS |
Dato-DXd new BLA submitted, NSQ BLA withdrawn | 12-Nov-2024 | 07:00 | RNS |
Tezspire nasal polyps trial met primary endpoints | 08-Nov-2024 | 07:00 | RNS |
AZN share price movement | 05-Nov-2024 | 16:49 | RNS |
Total Voting Rights | 01-Nov-2024 | 15:00 | RNS |
AZN China President under investigation | 30-Oct-2024 | 13:00 | RNS |
Wainzua recommended for approval in the EU | 21-Oct-2024 | 07:00 | RNS |
AstraZeneca licenses lipid lowering Lp(a) asset | 07-Oct-2024 | 09:30 | RNS |
Currency | UK Pounds |
Share Price | 10,000.00p |
Change Today | 31.00p |
% Change | 0.31 % |
52 Week High | 13,276.00p |
52 Week Low | 9,501.00p |
Volume | 1,081,359 |
Shares Issued | 1,550.30m |
Market Cap | £155,030m |
Beta | 0.87 |
RiskGrade | 123 |
Value |
---|
Price Trend |
---|
Income |
---|
Growth |
---|
Strong Buy | 9 |
Buy | 15 |
Neutral | 5 |
Sell | 0 |
Strong Sell | 1 |
Total | 30 |
Latest | Previous | |
---|---|---|
1st Interim | 2nd Interim | |
Ex-Div | 08-Aug-24 | 22-Feb-24 |
Paid | 09-Sep-24 | 25-Mar-24 |
Amount | 100.00¢ | 197.00¢ |
Time | Volume / Share Price |
13:04 | 99 @ 10,000.00p |
13:04 | 62 @ 10,002.00p |
13:04 | 72 @ 10,002.00p |
13:04 | 106 @ 10,002.00p |
13:04 | 43 @ 10,004.00p |
You are here: research